Immunogenicity and safety of the fourth dose of quadrivalent human papillomavirus (HPV) vaccine in immunosuppressed women who did not seroconvert after three doses
2024

Fourth Dose of HPV Vaccine in Immunosuppressed Women

Sample size: 23 publication Evidence: low

Author Information

Author(s): LĂ­via Zignago Moreira dos Santos, Camila Cristina Martini Rodrigues, Karina Takesaki Miyaji, Vanessa Infante, Camila de Melo Picone, Amanda Nazareth Lara, Carina Eklund, Hanna Kann, Joakim Dillner, Philippe Mayaud, Ana Marli Christovam Sartori

Primary Institution: Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil

Hypothesis

Does a fourth dose of the quadrivalent HPV vaccine improve immunogenicity in immunosuppressed women who did not seroconvert after three doses?

Conclusion

The fourth dose of the HPV vaccine was safe but resulted in seroconversion in only a few immunosuppressed women who had not seroconverted after three doses.

Supporting Evidence

  • Only 2 out of 10 women seroconverted to HPV6 after the fourth dose.
  • 3 out of 10 women seroconverted to HPV11 after the fourth dose.
  • 3 out of 10 women seroconverted to HPV16 after the fourth dose.
  • 6 out of 18 women seroconverted to HPV18 after the fourth dose.
  • Only three participants reported adverse events, none serious.

Takeaway

This study looked at whether giving a fourth dose of the HPV vaccine helps women with weakened immune systems who didn't respond to the first three doses. It found that only a few of them developed immunity after the fourth shot.

Methodology

An open-label, not-controlled trial evaluated the safety and immunogenicity of the fourth dose of the 4vHPV vaccine in immunosuppressed women who had not seroconverted after three doses.

Limitations

Inclusion occurred during the COVID-19 pandemic, leading to loss of eligible participants; cellular immunity responses were not evaluated; and there was an inclusion error with five participants who had already seroconverted.

Participant Demographics

{"median_age":38,"skin_color_distribution":{"white":73.9,"black":8.6,"brown":17.3},"median_schooling_duration":11,"comorbidities":{"hypertension":43.5}}

Digital Object Identifier (DOI)

10.3389/fcimb.2024.1451308

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication